Laurus Labs FY21 Annual Report Takeaways ๐Ÿ”ฌ

'Capex plans are already under way to increase capacity by 1.8x by 2022'

Hit the 'retweet' & help us educate more investors.

A Thread ๐Ÿงต๐Ÿ‘‡

1/ About the company:

Leadership position in generic APIs with a major focus on Antiretroviral drugs, Hepatitis C & Oncology drugs

FDF: Moved up the value chain in formulations

Synthesis (CDMO): KSMs, Intermediates & APIs to pharma innovators.

Bio: Recombinant products
2/ Strengths of the business:

Robust R&D & Process chemistry skills
Compliance that meets the most stringent regulatory expectations (USFDA, etc)
Long-standing relationships | Top 10 global pharma cos. catered

750+ scientists (R&D) | 61 DMFs | 27 ANDAs | 150 patents (292 filed)
3/ APIs: 54% of rev

- Leaders in various high-value & high-volume APIs.
- 4 high potent manufacturing facilities: 4186 KL, increasing capacity by 24% (Strong demand)
- ARV APIs were up 70% | Onco APIs up 25% | Other APIs up 56% (higher contract manufacturing orders from ๐Ÿ‡ช๐Ÿ‡บ)
4/ Formulations: 35% of rev

- Backwardly integrated: in house APIs
- Sales to LMIC, ๐Ÿ‡บ๐Ÿ‡ธ & ๐Ÿ‡ช๐Ÿ‡บ
- 27 ANDA filled: 9 approved+ 8 tentative.
- Capacity of 5 Billion units/yr, Increasing capacity by 100%
- Sales up 102% (growth across markets)
- Launched TLE 400 in the LMIC market
5/ Synthesis: 11% of rev

- CDMO services for global pharma with 50 active projects
- Commercial supplies ongoing for 4 products
- Sales up 35% due to client additions & increased commercialisations

During the year, acquired 73% of Richcore Lifesciences & renames it Laurus Bio.
6/ Manufacturing:

7 manufacturing plants in Andhra Pradesh & 1 plant in Hyderabad+ a kilo lab at the Hyderabad R&D center.

Future capacities: Debottlenecking to increase by 15% by Q1FY22 & further increases over the next 3 years.

Increasing capacity by 80% in 2022 ๐Ÿงช
7/ Laurus' journey of 15 years:

From ARV API company to API to Pharmaceutical company

Increased reactor volumes by 20 in 10 years
USFDA manufacturing sites from 1 to 5
Team strength 6 times
DMFs 5 times.
8/ Numbers that matter:

Sales up 70% YoY
33% EBITDA margin
Pat up 286% & Strong Cashflows
Strong Return ratios
4% of turnover invested in R&D

Growth Engines ->
9/ From the desk of the CEO (Dr. Chava)

- Formulation segment grew from 5cr to 825crs in 2 years ๐Ÿคฏ: tender businesses
- Acquisition of Richcore: In 5yrs want to use its capabilities to do biologics at a scale
- Setting up a dedicated R&D center & manufacturing for synthesis
10/ Trends in which the co. is betting on

- Demographics: An increasingly ageing population
- Changing supply chains: ๐Ÿ‡จ๐Ÿ‡ณ+1, etc
- Digital adoption across business operations
- Pressure on govt. budgets: decreasing medicine prices (generics market share to ๐Ÿš€)
- CDMO adoption.
11/ ARV opportunity & how the company is playing it: 12 APIs covering both 1st line & 2nd line treatment regimens.

Same for the Nutraceutical/dietary supplements
& cosmeceutical segments
12/ Strategies (Short & Long term)

The company running in the right direction, let's see if the management has more surprises under their sleeves.

End of Thread.
Laurus Labs Q4FY21 Concall Takeaways: https://t.co/1qU2RSChqw

Laurus Labs Q4FY21 results:
https://t.co/xGojyaTaeU

More from JST Investments

More from Lauruslabs

You May Also Like

Department List of UCAS-China PROFESSORs for ANSO, CSC and UCAS (fully or partial) Scholarship Acceptance
1) UCAS School of physical sciences Professor
https://t.co/9X8OheIvRw
2) UCAS School of mathematical sciences Professor

3) UCAS School of nuclear sciences and technology
https://t.co/nQH8JnewcJ
4) UCAS School of astronomy and space sciences
https://t.co/7Ikc6CuKHZ
5) UCAS School of engineering

6) Geotechnical Engineering Teaching and Research Office
https://t.co/jBCJW7UKlQ
7) Multi-scale Mechanics Teaching and Research Section
https://t.co/eqfQnX1LEQ
๐Ÿ˜Ž Microgravity Science Teaching and Research

9) High temperature gas dynamics teaching and research section
https://t.co/tVIdKgTPl3
10) Department of Biomechanics and Medical Engineering
https://t.co/ubW4xhZY2R
11) Ocean Engineering Teaching and Research

12) Department of Dynamics and Advanced Manufacturing
https://t.co/42BKXEugGv
13) Refrigeration and Cryogenic Engineering Teaching and Research Office
https://t.co/pZdUXFTvw3
14) Power Machinery and Engineering Teaching and Research
MASTER THREAD on Short Strangles.

Curated the best tweets from the best traders who are exceptional at managing strangles.

โ€ข Positional Strangles
โ€ข Intraday Strangles
โ€ข Position Sizing
โ€ข How to do Adjustments
โ€ข Plenty of Examples
โ€ข When to avoid
โ€ข Exit Criteria

How to sell Strangles in weekly expiry as explained by boss himself. @Mitesh_Engr

โ€ข When to sell
โ€ข How to do Adjustments
โ€ข Exit


Beautiful explanation on positional option selling by @Mitesh_Engr
Sir on how to sell low premium strangles yourself without paying anyone. This is a free mini course in


1st Live example of managing a strangle by Mitesh Sir. @Mitesh_Engr

โ€ข Sold Strangles 20% cap used
โ€ข Added 20% cap more when in profit
โ€ข Booked profitable leg and rolled up
โ€ข Kept rolling up profitable leg
โ€ข Booked loss in calls
โ€ข Sold only


2nd example by @Mitesh_Engr Sir on converting a directional trade into strangles. Option Sellers can use this for consistent profit.

โ€ข Identified a reversal and sold puts

โ€ข Puts decayed a lot

โ€ข When achieved 2% profit through puts then sold